Product Information
RAMIPRIL 1.25 MG CAPSULE is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.0804 per EA under NDC 57237022230. Its NADAC has been published 478 times since Aug 9, 2017.
FDA first approved this application on Jun 8, 2011. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
1.25 mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
57237022230
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RAMIPRILApproval Type
Generic (ANDA)
FDA Application
ANDA091604FDA Approved
6/8/2011
TE Code
AB
On Market Since
6/8/2011
Pharmacological Classes
Price Statistics
The NADAC for RAMIPRIL 1.25 MG CAPSULE has been published 478 times since Aug 9, 2017, and over the history we have for it it has declined 51.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0804 per EA |
|---|---|
| All-time high | $0.1737 (Dec 13, 2017) |
| All-time low | $0.0626 (Jul 17, 2024) |
| 52-week high | $0.0989 |
| 52-week low | $0.0778 |
| Median price | $0.1054 |
| Average price | $0.1110 |
| Largest weekly change | +82.1% (Mar 20, 2024) |
| Weeks tracked | 478 |
| Tracking since | Aug 9, 2017 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Ramipril market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Angiotensin Converting Enzyme Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RAMIPRIL 1.25 MG CAPSULE?
The current National Average Drug Acquisition Cost (NADAC) for RAMIPRIL 1.25 MG CAPSULE, manufactured by Rising Pharma Holdings Inc., is $0.0804 per EA (NDC 57237022230), effective Sep 30, 2026.
How has the price of RAMIPRIL 1.25 MG CAPSULE changed over time?
Over the history we have for it, the NADAC for RAMIPRIL 1.25 MG CAPSULE has declined 51.4%. It has been tracked across 478 weekly CMS publications since Aug 9, 2017.
What are the highest and lowest recorded NADAC prices for RAMIPRIL 1.25 MG CAPSULE?
Since Aug 9, 2017, the NADAC for RAMIPRIL 1.25 MG CAPSULE has ranged from a low of $0.0626 (Jul 17, 2024) to a high of $0.1737 (Dec 13, 2017), with a median of $0.1054 per EA.
Are there cheaper alternatives to RAMIPRIL 1.25 MG CAPSULE?
7 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RAMIPRIL 1.25 MG CAPSULE in a comparable dosage form, but none are currently priced below it.
Who manufactures RAMIPRIL 1.25 MG CAPSULE?
RAMIPRIL 1.25 MG CAPSULE (NDC 57237022230) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.